Effient trial by Daiichi, Lilly fails to meet primary endpoint

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 27 Aug, 2012

Singapore: The TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarct...Read more

Astellas Pharma opens office in Singapore

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2013

Singapore: Astellas Pharma, Japan's pharmaceutical giant with net sales of $10.7 billion and net income of $881 million as at March 31, 2013, has opened its office in Singapore. Astellas w...Read more

A*STAR, GSK develop medicines for emerging markets

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 09 Apr, 2013

Singapore: GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (E...Read more

Aussie firm gets TGA approval for pancreatic cancer drug

Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 18 Mar, 2014

Singapore: Australian biopharmaceutical company, Specialised Therapeutics Australia (STA), has recieved Therapeutic Goods Administration (TGA) approval for ABRAXANE (nanoparticle albumin-bo...Read more

Pharmaxis gets grants for fibrotic research

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jul, 2013

Singapore: Australian pharmaceutical company Pharmaxis' research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Coun...Read more

Regenerative Therapy for heart failure enters Ph III Trial

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

Singapore: Belgian biotechnology company Cardio3 BioSciences (C3BS) has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congest...Read more

Mesoblast to set up stem cell drug plant in Singapore

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 May, 2014

Singapore: Australian regenerative drug company, Mesoblast, is planning to expand its global manufacturing base and the company is in dialogues with Singapore Economic Development Board (ED...Read more

Sanford-Burnham, Daiichi form new alliance

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 May, 2014

Singapore: US based Sanford-Burnham Medical Research Institute and Japan's Daiichi Sankyo have formed a three year discovery and pre-clinical drug development partnership for cardiovascular...Read more

Boehringer, Eli Lilly to evaluate Trajenta for type 2 diabetes

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

Singapore: Boehringer Ingelheim and Eli Lilly have initiated phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albumin...Read more

Taiwan firm NCE to get priority review in China

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

Singapore: Taiwan Liposome Company's multi-mechanistic anti-cancer new chemical entity Lipotecan has been accepted into the "Green Path" program by the Chinese State Food and Drug Administr...Read more

Astrazeneca, China university in research deal

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 19 Dec, 2012

Singapore: AstraZeneca has signed a research collaboration with Fudan University, one of China's leading academic institutions in the area of cardiovascular diseases (CVDs). CVDs are a lead...Read more

Phylogica extends collaboration with Janssen Biotech

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 31 Jan, 2013

Singapore: Phylogica, a leading Australian peptide drug discovery company, has extended its collaboration with Janssen Biotech and its affiliates to discover, develop and commercialize new ...Read more

AstraZeneca, BMS gets positive regulatory feedback on Type 2 diabetes drug

Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 29 Nov, 2013

Singapore: Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided AstraZeneca and Bristol-Myers Squibb a positive opinion recommending app...Read more

Regeneron acquires Sanofi eye care antibodies

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 May, 2013

Singapore: US-based Regeneron Pharmaceuticals has acquired exclusive rights to two families of novel antibodies from Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF ...Read more

Teva, Xenon enter $335 mn deal for pain drug

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2012

Singapore: Israel-based Teva Pharmaceutical and Canada-based Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is curre...Read more

Linaclotide phase III trial initiated in China

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Sep, 2013

Singapore: Ironwood Pharmaceuticals and AstraZeneca Pharmaceuticals have announced the initiation of a phase III clinical trial of linaclotide in China for the treatment of adults with irri...Read more

Singapore firm, Stehlin Foundation collaborate on anti-cancer drug

Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 15 Oct, 2013

Singapore: NanoMaterials Technology (NMT), a Singapore based company, has signed an exclusive material supply agreement with Houston-based CHRISTUS Stehlin Foundation for Cancer Research (S...Read more

AseaCyte gets BioSpectrum award for drug discovery efforts

Drug Discovery |  Influencers | By BioSpectrum Bureau  | 0 Comment | 15 Mar, 2013

A meeting between Dr Teo Soo Hwang, current CEO of AseaCyte; Dr Lee Hong Boon from Cancer Research Initiatives Foundation (CARIF), a non-profit cancer research institute in Malaysia; and Dr...Read more